Uncategorized

Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

by Business Wire • 2021/01/07 • 0 Comments

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is now available in national and regional U.S. pharmaceutical distribution centers. Patients

Full Story →

← Alcon Announces Launch of AcrySof IQ Vivity, the First and Only Non-Diffractive Extended Depth of Focus Intraocular Lens in the U.S.

Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development →

Post navigation